secwatch.observer — SEC 8-K summary
======================================

Issuer:     CRESCENT BIOPHARMA, INC. (CBIO)
CIK:        0001253689
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0001558370-24-006459
Event type: other
Sentiment:  neutral
Materiality: 0.35
Item codes: 5.03, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

GlycoMimetics stockholders approve increase in authorized shares to 150M and officer exculpation amendment
--------------------------------------------------------------------------------

- Stockholders voted to increase authorized common stock from 100M to 150M shares (49.3M for, 1.0M against).
- Amendment adding Delaware-law officer exculpation provision approved (36.2M for, 1.0M against, 13.2M broker non-votes).
- Directors Daniel Junius and Rachel King elected with 34.6M and 37.0M votes for, respectively.
- Ratification of Ernst & Young as independent auditor for FY2024 passed with 50.3M votes for.
- Advisory vote on executive compensation approved with 35.3M for, 1.9M against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/0001558370-24-006459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1253689/000155837024006459/glyc-20240501x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-24-006459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer